Federal award (DEFINITIVE CONTRACT, fiscal year 2023)
Recipient: CMC PHARMACEUTICALS, INC.
Awarding agency: Department of Defense / Department of the Army
Funding agency: Department of Defense / Department of the Army
Period of performance: 2023-06-27 to 2025-07-02
Current total value of award: $1094180.64
Description: MODIFICATION P00002 EXERCISES OPTIONAL CONTRACT LINE ITEM 0002 FOR CONTINUED RESEARCH OF PHARMACEUTICAL DEVELOPMENT, PLANNING, AND CMO IDENTIFICATION FOR THE EXPEDITED ADVANCEMENT OF A SCOPOLAMINE MULTI-DOSE-VIAL DRUG PRODUCT.